The NOPAIN Act: Implications for opioid use reduction in orthopedic surgery.

Q3 Medicine
Ahmed Nadeem-Tariq, Matt Michelberger, Christopher J Fang, Karen Nelson
{"title":"The NOPAIN Act: Implications for opioid use reduction in orthopedic surgery.","authors":"Ahmed Nadeem-Tariq, Matt Michelberger, Christopher J Fang, Karen Nelson","doi":"10.5055/jom.0989","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The opioid epidemic remains a critical public health issue, with orthopedic surgeons being among the highest prescribers of opioids for post-operative pain management.</p><p><strong>Objective: </strong>To elucidate the provisions of the Non-Opioid Prevent Addiction in the Nation (NOPAIN) Act and its implications for reducing opioid use in orthopedic surgery.</p><p><strong>Methods: </strong>A comprehensive review of the NOPAIN Act's legislative framework, historical opioid use in orthopedic practices, current nonopioid pain management strategies, and insights from relevant reports was conducted.</p><p><strong>Results: </strong>The NOPAIN Act, effective January 1, 2025, mandates Medicare reimbursement for Food and Drug Administration-approved nonopioid pain treatments at 106 percent of the average sales price (+6 percent) in hospital outpatient departments and ambulatory surgery centers. This legislation incentivizes the adoption of nonopioid alternatives, promoting multimodal analgesia and regional anesthesia techniques. The Act may improve patient outcomes, reduce opioid-related adverse events, and help offset institutional costs.</p><p><strong>Conclusion: </strong>Implementation of the NOPAIN Act may influence orthopedic surgeons in adopting evidence-based, nonopioid pain management protocols, enhancing patient outcomes and contributing to national efforts against the opioid crisis. The Act's financial incentives and structured reimbursement framework may contribute to the transition toward safer practices.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 2","pages":"141-150"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of opioid management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5055/jom.0989","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The opioid epidemic remains a critical public health issue, with orthopedic surgeons being among the highest prescribers of opioids for post-operative pain management.

Objective: To elucidate the provisions of the Non-Opioid Prevent Addiction in the Nation (NOPAIN) Act and its implications for reducing opioid use in orthopedic surgery.

Methods: A comprehensive review of the NOPAIN Act's legislative framework, historical opioid use in orthopedic practices, current nonopioid pain management strategies, and insights from relevant reports was conducted.

Results: The NOPAIN Act, effective January 1, 2025, mandates Medicare reimbursement for Food and Drug Administration-approved nonopioid pain treatments at 106 percent of the average sales price (+6 percent) in hospital outpatient departments and ambulatory surgery centers. This legislation incentivizes the adoption of nonopioid alternatives, promoting multimodal analgesia and regional anesthesia techniques. The Act may improve patient outcomes, reduce opioid-related adverse events, and help offset institutional costs.

Conclusion: Implementation of the NOPAIN Act may influence orthopedic surgeons in adopting evidence-based, nonopioid pain management protocols, enhancing patient outcomes and contributing to national efforts against the opioid crisis. The Act's financial incentives and structured reimbursement framework may contribute to the transition toward safer practices.

NOPAIN法案:对骨科手术中阿片类药物使用减少的影响。
背景:阿片类药物流行仍然是一个重要的公共卫生问题,骨科医生是阿片类药物用于术后疼痛管理的最高处方者之一。目的:阐明国家非阿片类药物预防成瘾(NOPAIN)法案的规定及其对减少骨科手术中阿片类药物使用的影响。方法:全面回顾NOPAIN法案的立法框架、骨科实践中阿片类药物的历史使用、当前非阿片类药物疼痛管理策略,并从相关报告中获得见解。结果:NOPAIN法案于2025年1月1日生效,要求医疗保险以医院门诊部和门诊手术中心平均销售价格的106%(+ 6%)报销食品和药物管理局批准的非阿片类疼痛治疗。这项立法鼓励采用非阿片类药物替代品,促进多模式镇痛和区域麻醉技术。该法案可以改善患者预后,减少阿片类药物相关不良事件,并有助于抵消机构成本。结论:NOPAIN法案的实施可能会影响骨科医生采用基于证据的非阿片类疼痛管理方案,提高患者的治疗效果,并为国家应对阿片类药物危机做出贡献。该法案的财政激励和结构化报销框架可能有助于向更安全的做法过渡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of opioid management
Journal of opioid management Medicine-Anesthesiology and Pain Medicine
CiteScore
1.00
自引率
0.00%
发文量
54
期刊介绍: The Journal of Opioid Management deals with all aspects of opioids. From basic science, pre-clinical, clinical, abuse, compliance and addiction medicine, the journal provides and unbiased forum for researchers and clinicians to explore and manage the complexities of opioid prescription.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书